Login to Your Account



Financings Roundup


Friday, June 10, 2011
Ambit Biosciences Corp., of San Diego, withdrew its proposed initial public offering, stating that the current market was not "sufficiently attractive." Ambit filed its S-1 last year, hoping to raise $86 million to fund its portion of pivotal trials for quizartinib, being developed with partner Astellas Pharma Inc., of Tokyo, for acute myeloid leukemia.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription